| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.04 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.04 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.06 | 0.04 |
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | 0.39 | 0.04 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.096 | 0.04 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.04 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.04 |